Monte Rosa Therapeutics, Inc. GLUE
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Monte Rosa Therapeutics, Inc. (GLUE) is a healthcare company listed in the US with a market value of about $801M. In the twelve months to September 30, 2026 it had revenue of $70M and net income of -$131M, a net margin of -186.2%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -29%.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 76% over three years (dilution for shareholders). It spends 114% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $70M | $124M | $76M | $0 | — | — | — |
| Net income | -$131M | -$39M | -$73M | -$135M | -$109M | -$74M | -$36M |
| Free cash flow | -$174M | -$27M | $38M | -$63M | -$105M | -$69M | -$26M |
| EPS (diluted) | $-1.40 | $-0.46 | $-0.98 | $-2.63 | $-2.30 | $-2.96 | $-23.65 |
| Net margin | -186.2% | -31.2% | -96.1% | — | — | — | — |
| ROIC | — | -19.4% | -24.1% | -50.2% | -35.3% | -16.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $25.38, 171% above the current price; targets range from $15.00 to $37.00; the consensus rating is “Strong buy”; expected EPS is $-1.02 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Monte Rosa Therapeutics pay a dividend?
Not currently.
Is Monte Rosa Therapeutics a good stock to buy?
We do not give buy or sell advice. Monte Rosa Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.